Evidence map›Paper›PMID 42780341›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Long-Term Efficacy and Allograft Loss after Immune Checkpoint Inhibitor Therapy in Solid Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma.

Hannah Wu, Molly Murphy, Corentin Becot, Angela Fragano, Ethan H S Lin, Sruthi Surapaneni, Daniel Shirvani, Christine Cimoch, Ross Merkin, Sonia Cohen and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hannah WuCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.
Molly MurphyDepartment of Otolaryngology-Head and Neck Surgery, Mass Eye and Ear ∣ Mass General Brigham, Boston, Massachusetts, USA.
Corentin BecotDepartment of Otolaryngology-Head and Neck Surgery, Mass Eye and Ear ∣ Mass General Brigham, Boston, Massachusetts, USA.
Angela FraganoDepartment of Otolaryngology-Head and Neck Surgery, Mass Eye and Ear ∣ Mass General Brigham, Boston, Massachusetts, USA.
Ethan H S LinDepartment of Otolaryngology-Head and Neck Surgery, Mass Eye and Ear ∣ Mass General Brigham, Boston, Massachusetts, USA.
Sruthi SurapaneniDepartment of Otolaryngology-Head and Neck Surgery, Mass Eye and Ear ∣ Mass General Brigham, Boston, Massachusetts, USA.
Daniel ShirvaniDepartment of Otolaryngology-Head and Neck Surgery, Mass Eye and Ear ∣ Mass General Brigham, Boston, Massachusetts, USA.
Christine CimochDepartment of Otolaryngology-Head and Neck Surgery, Mass Eye and Ear ∣ Mass General Brigham, Boston, Massachusetts, USA.
Ross MerkinDepartment of Medicine, Division of Hematology and Oncology, Mass General Brigham Center Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Sonia CohenDepartment of Surgery, Massachusetts General Hospital ∣ Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.
Winfred WilliamsDepartment of Nephrology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Kevin EmerickDepartment of Otolaryngology-Head and Neck Surgery, Mass Eye and Ear ∣ Mass General Brigham, Boston, Massachusetts, USA.
Howard L KaufmanDepartment of Otolaryngology-Head and Neck Surgery, Mass Eye and Ear ∣ Mass General Brigham, Boston, Massachusetts, USA.ORCID 0000-0003-1131-004X
Sophia Z ShalhoutDepartment of Otolaryngology-Head and Neck Surgery, Mass Eye and Ear ∣ Mass General Brigham, Boston, Massachusetts, USA.ORCID 0000-0002-2783-5265

Funding

AIM-AHEAD Coordinating Center - All Four CoresOT2OD032581 · OD · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI Paul Avillach, Bettina M. Beech · 2021 to 2026
$168.7M
NIH HHS OT2 OD032581
6 · The paper itself

Abstract

Background: Immune checkpoint inhibitors (ICIs) can provide effective treatment for advanced cutaneous squamous cell carcinoma (CSCC) in solid organ transplant recipients (SOTRs), but long-term oncologic and allograft outcomes remain poorly characterized. Objective: To evaluate long-term efficacy and allograft outcomes after ICI therapy in SOTRs with advanced CSCC. Methods: We conducted a retrospective cohort study of SOTRs with advanced CSCC treated with systemic ICI at Mass General Brigham from 2016-2025. Tumor response, survival, immune-related adverse events, immunosuppression modifications, rejection rate, and graft loss were assessed. Kidney graft failure was analyzed using competing-risk methods with death as a competing event. Results: Among 36 SOTRs, objective response rate was 44.4% (95% CI, 27.9%-61.9%), including 9 complete responses. At 3 years, progression-free, disease-specific, and overall survival were 18.6%, 65.8%, and 32.5%, respectively. Median follow-up was 42.1 months. Five patients experienced graft loss, all kidney recipients; 4 had biopsy-confirmed rejection. The 3-year cumulative incidence of kidney graft failure was 16.7% (95% CI, 2.9%-30.5%). Limitations: Retrospective design, modest sample size, and heterogeneous immunosuppression limited risk-factor analyses. Conclusion: ICI provided long-term CSCC control with a low rate of allograft loss, highlighting the need for longitudinal multidisciplinary management balancing oncologic benefit, graft preservation, and competing mortality risk.

Indexed as

Cutaneous squamous cell carcinomaGraft rejectionImmune checkpoint inhibitorImmunosuppressionRenal transplantSolid organ transplantation

Identifiers

PMID42780341
PMCPMC13596681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.